Japan Tissue Engineering Co (TSE:7774) Total Stockholders Equity: 円5,143 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:7774 Japan Tissue Engineering Co Ltd TSE:7774
57 GF Score
Price 円848.00
GF Value 円590.98
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Japan Tissue Engineering Co Total Stockholders Equity?

Japan Tissue Engineering Co TSE:7774 +3.16% 57 Total Stockholders Equity is 円5,143 Mil as of Jun. 2026. GuruFocus rates TSE:7774 with a GF Score™ of 57/100 and a GF Value™ of 円590.98 (Significantly Overvalued). The stock has 3 warning signs investors should review.

Japan Tissue Engineering Co's Total Stockholders Equity for the quarter that ended in Jun. 2026 was 円5,143 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Japan Tissue Engineering Co's Book Value per Share for the quarter that ended in Jun. 2026 was 円126.63. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Japan Tissue Engineering Co's Debt-to-Equity for the quarter that ended in Jun. 2026 was 0.00.

Japan Tissue Engineering Co  (TSE:7774) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Japan Tissue Engineering Co's Book Value per Share for the quarter that ended in Jun. 2026 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(5142.521-0)/40.60995
=126.63

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Japan Tissue Engineering Co's Debt-to-Equity for the quarter that ended in Jun. 2026 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 0) / 5142.521
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Japan Tissue Engineering Co Total Stockholders Equity Related Terms

Japan Tissue Engineering Co Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Japan Tissue Engineering Co's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Japan Tissue Engineering Co Total Stockholders Equity Chart

Japan Tissue Engineering Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6,666.49 5,937.17 6,080.34 5,825.04 5,090.28

Japan Tissue Engineering Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5,582.65 5,453.68 5,268.84 5,090.28 5,142.52
TSE:7774
57GF Score
Japan Tissue Engineering Co Ltd TSE:7774
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of 円5,143 Mil mean?
Japan Tissue Engineering Co (TSE:7774) has a Total Stockholders Equity of 円5,143 Mil as of Jun. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Japan Tissue Engineering Co and its competitors.
Is Japan Tissue Engineering Co's Total Stockholders Equity too high?
Japan Tissue Engineering Co's current Total Stockholders Equity is 円5,143 Mil. Overall, Japan Tissue Engineering Co has a GF Score™ of 57/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Japan Tissue Engineering Co's Total Stockholders Equity compare to VRTX and REGN?
Japan Tissue Engineering Co's Total Stockholders Equity of 円5,143 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Biotechnology company?
A good Total Stockholders Equity depends on the Biotechnology industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Japan Tissue Engineering Co and its competitors. Japan Tissue Engineering Co's current Total Stockholders Equity is 円5,143 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Japan Tissue Engineering Co stock overvalued right now?
Based on GuruFocus' analysis, Japan Tissue Engineering Co (TSE:7774) is currently considered Significantly Overvalued. The stock's GF Value™ is 円590.98, compared to a current price of 円848.00 — trading 43.5% above its estimated fair value. The current Total Stockholders Equity is 円5,143 Mil. Japan Tissue Engineering Co's overall GF Score™ is 57/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Japan Tissue Engineering Co (TSE:7774), the current Total Stockholders Equity is 円5,143 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Japan Tissue Engineering Co (TSE:7774) Overvalued in 2026?

Based on GuruFocus' analysis, Japan Tissue Engineering Co stock appears to be overvalued. The current stock price of 円848.00 is trading 43.5% above its estimated GF Value™ of 円590.98. GuruFocus considers Japan Tissue Engineering Co to be Significantly Overvalued.

Key valuation signals for TSE:7774:

  • Total Stockholders Equity: 円5,143 Mil
  • GF Value™: 円590.98 vs. price of 円848.00 (43.5% above fair value)
  • GF Score™: 57/100 with 3 warning signs

No single metric tells the full story. See the TSE:7774 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Japan Tissue Engineering Co Business Description

Address 6-209-1 Miyakitadori, Gamagori, Aichi, JPN, 443-0022
Japan Tissue Engineering Co Ltd is a bio-venture enterprise. It is engaged in the development, manufacture, and sale of tissue-engineered medical products and related products. It operates through the Regenerative Medicine, and Research and Development support business segments. The main business goal is to use autologous culturing techniques to develop tissue-engineered medical products and then to manufacture and sell these same tissue-engineered products to medical institutions for medical treatment. The company's tissue-engineered medical products are used in autologous transplant cases, where living cells are taken from the actual patient himself, cultured and then transplanted back to that same patient.
57GF Score

Get the complete analysis for TSE:7774

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円848.00
Price
円590.98
GF Value